Ph.D. Vimal Mehta - 14 Sep 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: CEO and President, Director
Signature: /s/ Richard Steinhart, as Attorney in Fact for Vimal Mehta, Ph.D.
Issuer symbol: BTAI
Transactions as of: 14 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 18 Sep 2023, 16:47:09 UTC
Previous filing: 16 Jun 2023
Next filing: 18 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTAI	Common Stock	Options Exercise		+2,610	+9.7%		29,613	14 Sep 2023	Direct	F1, F2
holding	BTAI	Common Stock						2,000	14 Sep 2023	By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTAI	Restricted Stock Units	Options Exercise	$0	-2,610	-9.1%	$0.000000	26,094	14 Sep 2023	Common Stock	2,610		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	Represents adjustment in number of shares to correct an inadvertent error in the number of shares directly owned following the reported transaction in the Form 4 filed on May 24, 2023 and Form 4s filed thereafter.
F3	On March 14, 2022, the Reporting Person was granted 41,750 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.